Hold Rating Maintained for Synlogic Amidst Setbacks and Financial Uncertainties
Hold Rating on Synlogic Amidst Lead Program Discontinuation and Strategic Uncertainties
Synlogic Analyst Ratings
H.C. Wainwright Upgrades Synlogic (SYBX) to a Hold
Hold Rating on Synlogic Amid Discontinued Lead Program and Reduced Price Target
Synlogic Shares Downgraded After Trial Discontinuation
Synlogic Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Fusion Pharmaceuticals (FUSN), Enanta Pharmaceuticals (ENTA) and Synlogic (SYBX)
Synlogic Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Harrow Health (HROW), Synlogic (SYBX)
Progressive Synpheny-3 Trial and Extended Patent Protection Propel Buy Rating for Synlogic
Synlogic's Financial Strength and Promising Clinical Trials Bolster Buy Rating
Chardan Capital Reiterates Buy on Synlogic, Maintains $6 Price Target
Synlogic Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: BioLife Solutions (BLFS), Synlogic (SYBX)
Synlogic Analyst Ratings
Synlogic (SYBX) Receives a Buy From H.C. Wainwright
The Latest Analyst Ratings for Synlogic
Synlogic Analyst Ratings
H.C. Wainwright Remains a Buy on Synlogic (SYBX)
No Data